REG - Yourgene Health PLC - De-listing and cancellation of trading of Shares

Yourgene HealthAnnouncement

11/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230911:nRSK8955La&default-theme=true

RNS Number : 8955L  Yourgene Health PLC  11 September 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE
A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

FOR IMMEDIATE RELEASE

11 September 2023

RECOMMENDED CASH OFFER

for

Yourgene Health plc ("Yourgene")

by

Novacyt UK Holdings Limited

(a wholly-owned subsidiary of Novacyt S.A. ("Novacyt"))

to be effected by means of a Scheme of Arrangement

under Part 26 of the Companies Act 2006

 

De-listing and cancellation of trading of Yourgene Shares

 

Further to the announcement made by Yourgene on 8 September 2023 that the
Scheme has now become Effective in accordance with its terms, Yourgene
announces that, following an application to the London Stock Exchange, the
admission to trading on AIM of Yourgene Shares has been cancelled with effect
from 7.00 a.m. today, 11 September 2023.

 

It is intended that Yourgene will be re-registered as a private company
limited by its shares under the relevant provisions of the Companies Act 2006.

 

Capitalised terms used in this Announcement shall, unless otherwise defined,
have the same meaning as set out in the scheme document published by Yourgene
on 27 July 2023 (a copy of which is available on Yourgene's website at
https://yourgenehealth.com/our-investors/offer-for-yourgene-health-plc/
(https://yourgenehealth.com/our-investors/offer-for-yourgene-health-plc/) ).
All references to times in this announcement are to London time.

 

 

Enquiries:

 Yourgene
 Lyn Rees (Chief Executive Officer)                                             c/o Stifel
 Stifel (Rule 3 Adviser and Sole Financial Adviser to Yourgene)
 Nicholas Moore / Samira Essebiyea / William Palmer-Brown (Healthcare           Tel: +44 (0) 20 7710 7600
 Investment Banking)

 Matthew Blawat / Ben Good (UK Investment Banking)
 Cairn (Nominated Adviser to Yourgene)
 Liam Murray / Ludovico Lazzaretti                                              Tel: +44 (0) 20 7213 0880
 Walbrook PR Limited (Media and Investor Relations for Yourgene)
 Alice Woodings / Lianne Applegarth                                             Tel: +44 (0) 20 7933 8780 or yourgene@walbrookpr.com
                                                                                (mailto:yourgene@walbrookpr.com)

                                                                                Mob: +44 (0) 7407 804 654 / +44 (0) 7584 391 303
 Novacyt
 James Wakefield (Chairman)                                                     c/o Numis

 James McCarthy (acting Chief Executive Officer)
 Numis (Financial Adviser and Joint Broker to Novacyt and Financial Adviser to
 Novacyt UK)
 Freddie Barnfield / Stuart Ord / Duncan Monteith / Jack McLaren                Tel: +44 (0) 20 7260 1000
 S.P. Angel Corporate Finance LLP (Nominated Adviser and Joint Broker to
 Novacyt)
 Matthew Johnson / Charlie Bouverat (Corporate Finance)                         Tel: +44 (0) 20 3470 0470

 Vadim Alexandre / Rob Rees (Corporate Broking)
 Walbrook PR Limited (Media and Investor Relations for Novacyt)
 Paul McManus / Stephanie Cuthbert / Phil Marriage                              Tel: +44 (0) 20 7933 8780 or novacyt@walbrookpr.com
                                                                                (mailto:novacyt@walbrookpr.com)

Addleshaw Goddard LLP is providing legal advice to Yourgene.

Stephenson Harwood LLP is providing legal advice to Novacyt and Novacyt UK.

Important Notices

Numis Securities Limited ("Numis"), which is authorised and regulated in the
United Kingdom by the FCA, is acting as financial adviser to Novacyt and
Novacyt UK and no one else in connection with the matters described in this
Announcement. In connection with such matters, Numis will not regard any other
person as its client, nor will it be responsible to anyone other than Novacyt
and Novacyt UK for providing the protections afforded to clients of Numis or
for providing advice in connection with the contents of this Announcement or
any matter referred to in this Announcement. Neither Numis nor any of its
affiliates (nor their respective  directors, officers, employees or agents)
owes or accepts any duty, liability or responsibility whatsoever (whether
direct, indirect, consequential, whether in contract, in tort, under statute
or otherwise) to any person who is not a client of Numis in connection with
the Acquisition, the matters referred to in this Announcement, any statement
contained herein or otherwise. No representation or warranty, express or
implied, is made by Numis as to the contents of this Announcement.

S.P. Angel Corporate Finance LLP ("SP Angel"), which is authorised and
regulated in the United Kingdom by the FCA, is acting as nominated adviser and
joint broker to Novacyt and no one else in connection with the matters
described in this Announcement. and will not be responsible to anyone other
than Novacyt for providing the protections afforded to its clients or for
providing advice in relation to the Acquisition, the contents of this
Announcement or any other matters referred to in this Announcement. Neither SP
Angel nor any of its subsidiaries, branches or affiliates owes or accepts any
duty, liability or responsibility whatsoever (whether direct or indirect,
whether in contract, in tort, under statute or otherwise) to any person who is
not a client of SP Angel in connection with any matter referred to in this
Announcement or otherwise.

Stifel Nicolaus Europe Limited ("Stifel"), which is authorised and regulated
in the United Kingdom by the FCA, is acting exclusively for Yourgene and no
one else in connection with the matters described in this Announcement and
will not be responsible to anyone other than Yourgene for providing the
protections afforded to clients of Stifel nor for providing advice in
connection with the matters referred to herein. Neither Stifel nor any of its
affiliates owes or accepts any duty, liability or responsibility whatsoever
(whether direct or indirect, whether in contract, in tort, under statute or
otherwise) to any person who is not a client of Stifel in connection with this
Announcement, any statement contained herein, the Acquisition or otherwise. No
representation or warranty, express or implied, is made by Stifel as to the
contents of this Announcement.

Cairn Financial Advisers LLP ("Cairn"), which is authorised and regulated in
the United Kingdom by the FCA, is acting as nominated adviser exclusively for
Yourgene. Cairn's responsibilities as Yourgene's nominated adviser under the
AIM Rules for Companies and AIM Rules for Nominated Advisers are owed solely
to the London Stock Exchange and no other person. Cairn has not authorised and
is not making any representation or warranty, express or implied, as to the
contents of this Announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCMZGGLMRMGFZM